Answers are grounded in this paper and cite their sources.
In patients with HFrEF, the extent of vascular disease is associated with the risk for adverse cardiovascular outcomes. Empagliflozin offers cardiovascular and renal benefits in HFrEF across the extent of vascular disease, but this benefit is attenuated in those with polyvascular disease.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: